Vis enkel innførsel

dc.contributor.authorJacobsen, Cecilie
dc.contributor.authorZivadinov, Robert
dc.contributor.authorMyhr, Kjell-Morten
dc.contributor.authorDalaker, Turi Olene
dc.contributor.authorDalen, Ingvild
dc.contributor.authorBenedict, Ralph H.B.
dc.contributor.authorBergsland, Niels
dc.contributor.authorFarbu, Elisabeth
dc.date.accessioned2021-08-11T08:51:15Z
dc.date.available2021-08-11T08:51:15Z
dc.date.created2021-06-08T11:47:10Z
dc.date.issued2021
dc.identifier.issn2055-2173
dc.identifier.urihttps://hdl.handle.net/11250/2767322
dc.description.abstractObjectives To identify Magnetic Resonance Imaging (MRI), clinical and demographic biomarkers predictive of worsening information processing speed (IPS) as measured by Symbol Digit Modalities Test (SDMT). Methods Demographic, clinical data and 1.5 T MRI scans were collected in 76 patients at time of inclusion, and after 5 and 10 years. Global and tissue-specific volumes were calculated at each time point. For the primary outcome of analysis, SDMT was used. Results Worsening SDMT at 5-year follow-up was predicted by baseline age, Expanded Disability Status Scale (EDSS), SDMT, whole brain volume (WBV) and T2 lesion volume (LV), explaining 30.2% of the variance of SDMT. At 10-year follow-up, age, EDSS, grey matter volume (GMV) and T1 LV explained 39.4% of the variance of SDMT change. Conclusion This longitudinal study shows that baseline MRI-markers, demographic and clinical data can help predict worsening IPS. Identification of patients at risk of IPS decline is of importance as follow-up, treatment and rehabilitation can be optimized.en_US
dc.language.isoengen_US
dc.publisherSAGE Publicationsen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleBrain atrophy and clinical characteristics predicting SDMT performance in multiple sclerosis: A 10-year follow-up studyen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright The Author(s), 2021en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1177/2055217321992394
dc.identifier.cristin1914457
dc.source.journalMultiple Sclerosis Journal - Experimental, Translational and Clinicalen_US
dc.identifier.citationMultiple Sclerosis Journal - Experimental, Translational and Clinical. 2021, 7 (1).en_US
dc.source.volume7en_US
dc.source.issue1en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal